Scancell Holdings PLC on Tuesday said it has raised £11.9 million in total, from an open offer, placing, and subscription of shares.
Scancell is an Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease
On Tuesday, it has raised £1.2 million through an open offer of 11.1 million shares.
The open offer shares were priced at 11 pence each. Shares in Scancell were up 2.3% to 11.00p each on Tuesday afternoon.
Earlier in December, Scancell said it had raised £10.7 million from the placing and subscription of 97.0 million new shares at 11p each. At the time, it announced an open offer, to raise up to a further £2.0 million.
‘The funds raised today will further drive the company’s progress with its lead programmes, including SCIB1, which recently demonstrated an unprecedented objective response rate of 85% in patients with unresectable melanoma in initial data from the Scope study, and Modi-1 through its next clinical steps,’ said Chief Executive Officer Lindy Durrant at the start of December.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
